Evidence map›Paper›PMID 40796828›Full record

ArticleBMC medicine2025

Evaluating the effectiveness of international travel controls to identify MPXV-infected travelers: a simulation study.

Keisuke Ejima, Yuqian Wang, Akira Endo, Hiroaki Murayama, Yun Shan Goh, Alex R Cook, Yong Dam Jeong, Shingo Iwami, Hyeongki Park, Borame Sue Lee Dickens and 9 more

Abstract read
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Keisuke Ejima *Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. keisuke.ejima@ntu.edu.sg.
Yuqian Wang *Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Akira Endo *Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.
Hiroaki MurayamaSchool of Medicine, International University of Health and Welfare, Narita, Japan.
Yun Shan GohA*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Alex R CookNational Centre for Infectious Diseases, Singapore, Singapore.
Yong Dam JeongInterdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
Shingo IwamiInterdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
Hyeongki ParkInterdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
Borame Sue Lee DickensSaw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.
Shihui JinSaw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.
Jue Tao LimLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Conrad En Zuo ChanNational Centre for Infectious Diseases, Singapore, Singapore.
Po Ying ChiaLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Barnaby E YoungLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Yang YangShenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Martin ChioNational Skin Centre Singapore, Singapore, Singapore.
David Chien LyeLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Marco Ajelli *Laboratory for Computational Epidemiology and Public Health, Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, IN, USA.

Funding

Japan Science and Technology Agency JPMJPR22R3Japan Science and Technology Agency JPMJPR23R3Japan Society for the Promotion of Science JP22K17329Lee Kong Chian School of Medicine, Nanyang Technological University LKCMedicine-SUG, #022487-00001Ministry of Education - Singapore RLMOE100201900000001
6 · The paper itself

Abstract

backgroundIn August 2024, the World Health Organization (WHO) declared a public health emergency due to the rapid spread of mpox in Africa and beyond. International travel controls (ITCs), such as health screening and viral testing, could help avoid/delay the global spread of MPXV, fostering preparedness and response efforts. However, it is not clear whether the viral tests at immigration are sufficient to avoid introduction of MPXV and which samples should be used on the viral tests.

methodsWe conducted a simulation study using epidemiological and viral load data to assess the effectiveness of health screening and polymerase chain reaction (PCR) testing at immigration. The primary outcome was the proportion of MPXV-infected travelers identified under various international travel control policies. To estimate time-varying false-negative rates of PCR tests with different detection limits, we employed viral dynamics models calibrated to data from three anatomical sites: oropharynx, saliva, and rectum. Additionally, we simulated the effects of these control measures on the recommended duration of a post-entry monitoring period. Travelers were assumed to depart from mpox-affected countries, defined as those with ongoing MPXV transmission, potentially representing both historically endemic regions and countries with recent outbreaks.

resultsOur results show that under an endemic scenario, the combination of health screening and PCR testing using saliva swabs identifies approximately 74% of MPXV-infected travelers. Using rectal swabs slightly improves detection, identifying up to 79% of infected individuals. A comparable improvement can also be achieved by increasing test sensitivity (i.e., reducing the detection limit from 250 to 10 copies/mL). Based on the distribution of post-entry incubation periods, we estimated that travelers from mpox-affected regions should self-monitor and adopt precautionary behavior for at least 16 days to mitigate the risk of onward transmission.

conclusionsHealth screening and PCR testing at immigration are likely to miss a significant proportion of MPXV-infected travelers, thus a lengthy quarantine period would be required to prevent onward local transmission. Careful consideration on other factors such as economic costs and likelihood of widespread local outbreak will need to be weighed against the adoption of these measures to prevent local mpox transmission given MPXV transmissibility and severity.

Indexed as

TravelComputer SimulationHumansMass ScreeningPolymerase Chain ReactionViral LoadFalse negativeHealth screeningInternational travelMathematical modelMpoxMPXV transmissionPCR testingPublic healthQuarantine

Identifiers

PMID40796828
PMCPMC12344887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.